OmniAb, Inc. (OABI)

Market Cap	696.42M +176.4%
Revenue (ttm)	38.46M +67.0%
Net Income	-44.27M
EPS	-0.35
Shares Out	145.39M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,039,170
Open	4.660
Previous Close	4.660
Day's Range	4.590 - 4.915
52-Week Range	1.300 - 5.430
Beta	1.37
Analysts	Strong Buy
Price Target	8.33 (+73.9%)
Est. Earnings	Nov 3, 2026

About OABI

OmniAb, Inc., a biotechnology company, licenses discovery research technology to pharmaceutical and biotech companies, and academic institutions to enable the discovery of therapeutics in the United States, Europe, Japan, China, and Canada. The company’s technology platform creates and screens diverse antibody repertoires to identify optimal antibodies and other target-binding proteins for partners’ drug development efforts. Its OmniAb platform’s Biological Intelligence powers the immune systems of its proprietary and engineered transgenic anim...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2012
• Employees: 89
• Stock Exchange: Nasdaq
• Ticker Symbol: OABI
• Website: https://www.omniab.com

Financial Performance

In 2025, OmniAb's revenue was $18.67 million, a decrease of -29.27% compared to the previous year's $26.39 million. Losses were -$64.78 million, 4.43% more than in 2024.

Analyst Summary

According to 7 analysts, the average rating for OABI stock is "Strong Buy." The 12-month stock price target is $8.33, which is an increase of 73.90% from the latest price.

Price Target

$8.33

(73.90% upside)

Analyst Consensus: Strong Buy

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Oct 10, 2026

Data Sources Report a data error